The patient perspective

PREFER looks at how and when it is best to perform and include patient preferences in decision making during the medical product life cycle. We include patient stakeholders at every level of the project. The end-result will be recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies.

PREFER Recommendations

The PREFER Recommendations

Supporting the development of guidelines for structured patient input into decision-making for the pharmaceutical industry, regulatory authorities, health technology assessment bodies and reimbursement agencies!

PREFER Expert Network

The PREFER EXPERT NETWORK is a voluntary network of pharmaceutical companies, academic institutions, consultants, and patient representatives devoted to promoting the development and adoption of patient preferences in decision-making about medical products.

Developing recommendations

We are developing evidence-based recommendations to guide industry, regulatory authorities, HTA bodies, reimbursement agencies, and health care professionals. We start with work to assess methodologies. After that, we test them in clinical case studies. This work will be the basis for the recommendations we make.

Together with stakeholders

Denna puff länkar till sidor som ligger ett eller flera steg längre ner på samma gren i strukturträdet. Den kan också länka till genomgångssidor inom uu.se. Bildproportion: 16:9. Se till att rubriknivån är korrekt. Bildproportion: 16:9.

Through clinical case studies

Denna puff länkar till sidor som ligger ett eller flera steg längre ner på samma gren i strukturträdet. Den kan också länka till genomgångssidor inom uu.se. Bildproportion: 16:9. Se till att rubriknivån är korrekt. Bildproportion: 16:9.

FINDING OUT WHAT PATIENTS PREFER

Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five year public-private research project where academic researchers, HTA, patient organisations, and the pharmaceutical industry work together to find out when, and how patients’ treatment preferences can be used in medical product development.

We are looking forward to sharing our findings with you!

Mats G. Hansson, Uppsala University, Coordinator
Conny Berlin, Novartis, Project Leader

Blank

Innovative Medicines Initiative

PREFER is funded by the Innovative Medicines Initiative (IMI): a part of the EU Horizon 2020 Programme.

European Union

The academic research in PREFER is funded by Horizon 2020: the EU Framework Programme for Research and Innovation.

EFPIA

The pharmaceutical industry contributes equally to the PREFER project. Industry input to the IMI programme is organised by EFPIA.

Last modified:

CONTACT US

X: @IMI_PREFER

LinkedIn

YouTube

  •  
  • Disclaimer: This website and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.
  •  

PREFER

The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).